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Editorial

Zinc intake, microRNA dysregulation, and esophageal cancer
Louise Y. Fong, John L. Farber, and Carlo M. Croce

hyperplastic marked zinc deficient esophagus,
however, was not differentially expressed in the less
hyperplastic moderate/mild zinc deficient esophagus,
providing evidence that miRNA signatures distinguish
the highly hyperplastic esophageal phenotype induced
by marked deficiency from the less hyperplastic
esophageal phenotype induced by moderate and mild
zinc deficiency.
With exposure to NMBA, ~16% of moderate/mild-ZD
rats developed ESCC, an incidence greater than for
Zn-sufficient rats (0%) (P≤0.05) but lower than for
marked-ZD rats (68%) (P<0.001) (n=27 rats/cohort).
These data show a dose-response relationship between
the extent of zinc deficiency and ESCC development
and provide the first evidence that moderate to mild
zinc deficiency, combined with low doses of the
environmental carcinogen NMBA, produces ESCC.
Importantly, the high ESCC-burden, marked zinc
deficient esophagus had a 15-miRNA signature, with
strong to modest up-regulation of oncogenic miR-223,
-21, -31, -146a, -146b, -27a, -221, -27b, -194, -24, 203, -183, -130b, -106b, -22 (up 3.6 to 1.4 fold), that
resembled the human ESCC miRNAome. By contrast,
low ESCC-burden, moderate & mild-ZD esophagus
displayed, respectively, a 3-miRNA signature (miR223, -31, -27b) and a 2-miRNA signature (miR-223, 31) with modest up-regulation. Thus, miRNAsignatures can distinguish the divergent ESCC
progression in marked zinc deficiency versus
moderate/mild zinc deficiency rat cohorts, as well as
discriminate the hyperplastic marked deficiency
esophageal phenotype from the less hyperplastic
moderate/mild deficiency phenotype. Together, the
data showed that these miRNA signatures not only
differentiate stages of ESCC initiation and progression
but they also highlight the molecular impact of dietary
zinc deficiency on miRNA dysregulation in the
pathogenesis of ESCC. In addition, Fbxw7, Pdcd4,
and Stk40 (tumor-suppressor targets of miR-223, miR21 and miR-31, respectively) were down-regulated in
the markedly deficient cohort at the mRNA and
protein level and they were predicted to interact to
alter network of target proteins in cancer pathways.
The data are in accord with the finding that miR-223,
miR-21 and miR-31 expression levels play important
roles in ESCC and may be useful prognostic

Esophageal squamous cell carcinoma (ESCC) is a
deadly disease with a 5-year survival of only 10% [1].
Because of the absence of early symptoms, ESCC is
commonly diagnosed at an advanced stage. Thus, the
development of new prevention and therapeutic
approaches are urgently needed. Dietary zinc (Zn)
deficiency (ZD), a significant public health issue
affecting 31% of the global population [2], is
associated with an increased risk of ESCC
development [3]. Since marginal Zn deficiency is
prevalent in humans [4], it was important to learn the
effect of mild to moderate Zn deficiency on ESCC
etiology.
Our previous work, using rat model systems, has
advanced understanding of the role of Zn in ESCC
carcinogenesis. Zn deficiency promotes ESCC by
inducing an inflammatory gene signature with upregulation of cancer-associated inflammation genes &
an oncogenic microRNA (miRNA) signature featuring
up-regulation of oncogenic miR-31 [5]. Our recent
dose-response study [6] showed that miRNA
dysregulation and esophageal cancer development
depended on the extent of dietary Zn deficiency. This
tumorigenesis study used low doses of the
environmental
carcinogen
N-nitrosomethylbenzylamine (NMBA) in rats fed diets containing
different amounts of Zn (3, 6, 12, or 60 mg Zn/kg) to
represent marked-ZD, moderate-ZD, mild-ZD, and
Zn-sufficiency in human Zn nutrition. miRNA
expression profiling of human tumors has identified
signatures associated with staging, progression,
prognosis, and response to treatment [7].
We
correlated miRNA expression changes with the above
noted ZD doses and ZD-associated esophageal tumor
outcome by performing miRNA profiling of
esophageal mucosa from carcinogen-treated and
untreated rats at study endpoint. Marked zinc
deficiency (3 mg Zn/kg diet) alone induced a highly
proliferative/inflammatory esophagus accompanied by
an oncogenic 5-microRNA signature (miR-31, -223, 21, -146b, -146a). Moderate & mild zinc deficiency (6
& 12 mg Zn/kg diet) also induced sustained
hyperplasia and inflammation, albeit less pronounced
than marked deficiency, with a 2-microRNA signature
(miR-31, -146a). The oncomiR miR-21 that was
prominently overexpressed (up 4.2 fold) in the highly
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biomarkers and therapeutic targets for ESCC. Using
ChIP-seq and an antibody for histone mark H3K4me3,
we previously showed that in Zn-deficient esophagus,
the miR-31 promoter region and NF-κΒ binding site
were activated [5]. However, the mechanism(s) by
which miR-223 and miR-21 are upregulated by zinc
deficiency remains to be elucidated.
In summary, our recent work [6] showed for the first
time that ESCC development and the underlying
miRNA dysregulation are dependent on the extent of
dietary deficiency of the nutrient Zn. The data have
identified Zn deficiency-associated miRNA signatures
that may underlie the molecular pathogenesis of
ESCC in Zn-deficient populations. These findings
suggest that dietary Zn may have preventive and
therapeutic properties for ESCC.
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